Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $50.18M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.66M
Average 0.42M
Returns on capital
Corbus Pharmaceuticals Holdings, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-53.2%
avg -150.7%
ROIC
-57.2%
avg -160.0%
ROA
-46.7%
avg -87.1%
Analysis
ROA is currently the strongest return metric at -46.7% versus its period average of -87.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Yuval Cohen | Chief Executive Officer & Director | USD 1.04M | 51 | 157.32K | 1.25% |
Leonardo Viana Nicacio | Chief Medical Officer | USD 720.99K | 48 | 58.33K | 0.47% |
Sean F. Moran | Chief Financial Officer | USD 695.75K | 68 | 84.69K | 0.68% |
Ian Hodgson | Chief Operating Officer | — | 53 | 51.08K | 0.41% |
G. Scott Goeken | General Counsel & Corporate Secretary | — | — | — | — |
Nishant C. Saxena | Chief Business Officer | — | — | 77.90K | 0.62% |
Christina Bertsch | Vice President of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 16, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$126,254.94
Sells
14
$2.72M
Net Transaction Value
−$2.59M
Net selling
Most Active
Saxena Nishant C
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 29, 26Oct 29, 2026 | Cormorant Asset Management, LP Indirect | Sell | $1.7M$1,742,755.00 |
| Sep 14, 26Sep 14, 2026 | Ben Yong Direct | Sell | $15.7K$15,683.00 |
| Aug 11, 26Aug 11, 2026 | Saxena Nishant C Direct | Buy | $25K$25,036.44 |
| Aug 7, 26Aug 7, 2026 | Cohen Yuval Direct | Sell | $171.4K$171,395.70 |
| Aug 7, 26Aug 7, 2026 | Moran Sean F. Direct | Sell | $121K$120,970.80 |
| Jun 10, 26Jun 10, 2026 | Kung Winston Direct | Sell | $16K$16,033.16 |
| Jun 10, 26Jun 10, 2026 | Altmeyer Anne Direct | Sell | $19.1K$19,087.84 |
| Jun 10, 26Jun 10, 2026 | Jenkins John Kenneth Direct | Sell | $38K$37,985.76 |
| Jun 3, 26Jun 3, 2026 | Saxena Nishant C Direct | Buy | $68.2K$68,220.00 |
| Jun 2, 26Jun 2, 2026 | Saxena Nishant C Direct | Buy | $33K$32,998.50 |
1–10 of 17
Summary
Insiders reported 3 buys worth $126,254.94 and 14 sells worth $2.72M over the last 12 months. That adds up to net selling of $2.59M. Saxena Nishant C was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Corbus Pharmaceuticals Holdings, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CRBP's management, answered from reported figures.
Who manages CRBP?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) lists 7 active executives. The top listed executive is Leonardo Viana Nicacio, Chief Medical Officer.
Are CRBP insiders buying or selling?
Recent insider activity shows net buying of $67.67M.
Continue the stock analysis
Jump to another research area for this company.